Hello again – now a note about day 2 at the IAPO GPC 2016!
(International Alliance of Patients Organisations) Global Patients Conference 2016)
Sunday morning was devoted to UHC (Universal Health Coverage).  We had two presenters, from the WHO (World Health Organisation), Nittita Prasopa-Plaizier and Mario Ottigilo.    UHC is a global project with the goals :
  • health service coverage;
  • financial risk protection; and 
  • equity or coverage for the entire population.
I believe it was launched in 2008, and has an objective of being implemented by 2030!
You can learn more about it here: http://www.who.int/mediacentre/factsheets/fs395/en/
Nittita Prasopa-Plaizier, WHO, said there was a role for patient organisations in the UHC.  The role of ensuring that people understand their own health care system.  She also talked a lot about putting “the care back into health care” and beginning with the people.  She felt compassion is needed on both sides: Patients prepared, and Doctors attentive. As “Compassionate Care” in UK.
She said that the WHO does not work with patient organisations, but that was where IAPO came in.  IAPO is the go-between for WHO and organisations. 
Mario Ottigilo, WHO, talked about the roles of pharmaceutical companies and the private sector in health care.  There is a place for partnerships with private and pharmas for UHC.  Private companies can support  the UHC through training of healthcare professionals, capacity-building, and awareness campaigns.
Kawaldip Sehmi (IAPOvoice CEO) told us about his grandmother, who was known for tolerating someone until the next wedding party, when she would seek her very public revenge!  He told us to, “Speak up! You have the ability to embarrass the government at the wedding.  Embarrass them into listening to us!” 
Then there was a panel on the different approaches to innovation to health care.
Robert Johnstone, IAPO board member (and now an EPF board member), presented a patient’s view of the NHS (National Health Service in the UK). He talked about the great affection people have for the NHS in the UK, “we love it, especially interaction with doctors”.  NHS is a health system where care and medicine are free at delivery,  but Robert Johnstone said that too little money and effort, only 4% of the budget, is spent on prevention.  He continued, “”The NHS has become a fear-based system whereby ‘we have to treat you, just in case’ .”
Joshua Wamboga, Uganda Network of AIDS Service Organisations, talked about how Rwanda brought global health care just years after genocide.  
We then had two breakout sessions. 
For the first one, I attended the session, “Patient involvement in research: innovation in the drug development and access pathway”, chaired by Antonio Ciaglio, IAPO.
Antonio said in his opening words that patients need to be at the center of research and involved from the start.
Alison Lightbourne, IAPO, says that no matter what everyone says about patients being involved in research, patients are still at the “kids” table.  It will take work to get to more acceptance and involvement of patients.  We all want better drugs coming to market, so we have to work on ensuring that.  There are two projects at the moment that should help that, from IMI: Protect Project and the GetReal Project.
The Protect Project, The goal of PROTECT is to strengthen the monitoring of the benefit-risk of medicines in Europe, using new tools and methods that are profoundly patient-centric. http://www.imi-protect.eu/objectives.shtml
The GetReal Project, aims to show how robust new methods of RWE collection and synthesis could be adopted earlier in pharmaceutical R&D and the healthcare decision making process. Aim is to try and get “real world” info from patients in order to best tackle challenges.   https://www.imi-getreal.eu
IAPO believes that patients have unique needs, and they want to understand what matters to patients most. 
Jane Meijlink International Painful Bladder association, gave such an eye-opening presentation on the role patients can have in standardising terminology and definitions.  “Healthcare is a chain with multiple links and standardisation of terminology and definitions can have an impact on every link in the chain and therefore a major impact on the patients, the patient’s healthcare and ultimately the patient’s whole family.” 
Ricardo C Santiago, Health Insight in Brazil, gave a really fascinating presentation about a maternal health project, EUSAUDE, that includes health analysis. What is really special about this program, is they collect all the data and provide it to do valuable Maternal health analysis in Brazil, which has had an positive impact on maternal health are in Brazil.
–> Dr Santiago is a very good person to follow and to talk to about health data collection and data ownership, which was a recurring topic at this conference.
Kate Hallet of Quintiles, outlined their work.  She said she has been passionate about her work since started working on patient-centric trials in 2005 with lupus Europe! 
She said that Quintiles is creating an easy to search on platform for patients to find clinical trials.  It’s not live yet, but is supposed to be going live soon.  It provoked quite a bit of interest as the www.cinicaltrials.gov website is hard to decipher for a normal person.
There were comments and questions about two projects that IAPO is involved in: IMI, Innovative Medical Initiative (“Europe’s largest Public/private initiative”), aiming to speed up the time to market for new drugs; and PFMD, Patient Focused Development Coalition, which was launched Oct 2015. 
There was a comment that any patient going into the clinical research and/or trials has a very steep learning curve!  And it’s been that way for at least 25 years.  However, the GetReal project and Eupati should help.
Another comment was about the ownership of data being really one of the very key issues that should be addressed very quickly, we are already behind!  There is hope about sharing data and doing data analysis to be had from Big Data technology but we are far from the objective.
The second breakout session was small group networking, and the topic was defined by the attendees.  Our group ended up being the largest, on, “How do we create and sustain strong and capable patients’ organisations;”
After much discussion, the three point plan to ensure a healthy organisation was: 
  1. Have a clear strategic plan, which includes
    1. Shared vision
    2. Shared values
    3. Succession plan, (and make sure you transfer the knowledge! “As soon as you know something, share it with someone in the group.”)
  2. Human Resource (volunteers) Management is essential, with 
    1. Clear, ethical rules
    2. Recognition (say thanks)
  3. Communication
    1. Of strategic plan and vision
We also told IAPO and EPF that we need training and help, and perhaps they can develop a course.   That’s when Camille Bullot of the EPF told us about the upcoming training on “Transparency & Ethics”, and another one: 2016 EPF Regional Advocay Seminar: “Getting the patients’ message across to the national and European levels”.  Have a look here: http://www.eu-patient.eu/Events/
The final plenary concerned different approaches to patient involvement and access.
Penney Cowen, American Chronic Pain Association, showed us the new pain scales they have created and are trying to get accepted by all hospitals in the US. IN fact they have created many different tools for pain and other medical situations. Such good work, and so obvious it seemed strange that their scales hadn’t already been adopted!  https://theacpa.org/Communication-Tools
Victoria Pinkney- Atikinson, Patient Health Alliance of Non governmental Organisations, gave  a very inspiring speech about work that is being done in South Africa.  Very much of a “think global, act local” advocate, and a woman who believes we need to speak up, shout out, about what patients need.  “We patients are too moderate. We need to get active! To unzip our mouths!”  And “Patient groups need to be Watchdogs, not Lapdogs! ” 
Sylvie St-Laurent, Pfizer, spoke about the RA specific platforms.  Apparently they are really looking at involving patients pre-clinical trials and are actively training patients. 
We had the group photo and then the gala dinner for the end of day 2!

Live Facebook Feed

Comments Box SVG iconsUsed for the like, share, comment, and reaction icons

🧠 Brain fog is real.

For many people living with lupus, it affects everyday life, yet it has often remained difficult to measure.

✅ The new Lupus Brain Fog Severity Scale (LBFSS) is the first questionnaire designed specifically to assess brain fog in lupus.

🦋 Lupus Europe is proud to have contributed to its development through meaningful involvement of people living with lupus. It's another example of how patient perspectives help shape better research and better tools.

🎥 Watch Prof Laurent Arnaud and our Chair, Jeanette Andersen, explain why the LBFSS is such an important step forward in lupus care.

lupus.bmj.com/content/lupusscimed/13/2/e002148.full.pdf
... See MoreSee Less

🦋 Understanding lupus is crucial for effective management and self-management.

💁‍♀️ Many of us know what lupus is, and we’ve been learning from trusted resources like #Lupus100 and #LupusGPT.

🤔 But… how much do we really know about SLE?
Do we know as much as we think we do?

𝐓𝐫𝐲 #𝐒𝐋𝐀𝐊𝐄 𝐚𝐧𝐝 𝐟𝐢𝐧𝐝 𝐨𝐮𝐭❗

🎯 SLAKE (Systemic Lupus Assessment score for Essential Knowledge) is a quick and easy online tool designed for people living with lupus to test their knowledge and learn more about the disease.

📝 44 questions, randomly selected from a pool of 394
⏱️ Around 15 minutes to complete
🌍 Available in 20 languages
📊 A score for each lupus domain and an overall knowledge score

💡 Whether you're newly diagnosed or have been living with lupus for years, SLAKE helps you identify what you already know and where there is room to grow. It is not about passing or failing. It is a chance to learn more and feel more confident when taking part in decisions about your health.

📣 The SLAKE study is still open! By taking part, you are helping researchers understand which aspects of lupus are well understood and where important knowledge gaps remain.

These insights could help guide the potential development of better information resources and tools, tailored to the real needs of people living with lupus in different countries and regions.

SLAKE has been made possible thanks to the leadership of Prof Laurent Arnaud and Dr Antonin Satrin, and the collaboration of an international team of lupus experts and patient representatives.

🥰 Lupus Europe has proudly contributed to this project since the very beginning, and we encourage people living with lupus worldwide to take part while the study remains open.

🔗 Complete SLAKE today and let us know what you think!

lupusresearch.limequery.org/775349
... See MoreSee Less

☀️ As we close our #LupusUVprotection campaign, here is one important reminder:

👉 UV protection in lupus is not only about sunny beach days.

😶‍🌫️ UV exposure can happen on cloudy days, near some windows, while travelling by car, or through certain artificial light sources. And in some people with lupus, its effects may not appear immediately.

‼️ That is why clear, reliable information matters.

Whether you have questions about UV light, photosensitivity, skin symptoms, flares, fatigue, daily life with lupus, or many other lupus-related topics, Lupus Europe provides free, reliable and multilingual tools to support you:

🔹 #𝗟𝘂𝗽𝘂𝘀𝟭𝟬𝟬
Patient-friendly answers to 100 key questions about lupus, including sun exposure and UV protection
lupus100.org/en/questions/can-i-sunbathe-with-lupus

Created with lupus experts & patients. Available in 19 languages.

🔹 #𝗟𝘂𝗽𝘂𝘀𝗚𝗣𝗧
A free artificial intelligence tool to help people find reliable, valid lupus information in almost any language.:
lupusgpt.org/

🔹 #𝗘𝗮𝘀𝘆𝗟𝘂𝗽𝘂𝘀
Like LupusGPT, but designed to make the answers even easier to understand:
easy.lupusgpt.org/

🦋 Because lupus does not only affect clinic appointments. It affects everyday life.

✅ Stay informed. Ask questions. Use reliable resources.
... See MoreSee Less

Image attachment
Image attachment
Image attachment

✅ Yesterday Lupus Europe took part in the DORIS+ meeting in London, alongside clinicians, researchers and patient representatives working on a definition of deep remission in #SLE.

🌟 Lupus Europe was wonderfully represented by Jeanette Andersen, Chair of the Lupus Europe Board, Francesca Marchiori, Lupus Europe Board and PAN Member, Blanca Rubio, PAN Member and Zoe Karakikla-Mitsakou, Lupus Europe General Secretary.

🦋 This continues Lupus Europe involvement in the work on remission in lupus, building on the original DORIS initiative, where Lupus Europe also contributed.

🤔 But what is DORIS?

DORIS stands for Definitions Of Remission In SLE. It helped establish a clinical definition of remission in systemic lupus erythematosus.

🐠 DORIS+ builds on that foundation and explores the concept of deep remission.

💁‍♀️ Since the original DORIS definition was published, emerging evidence has suggested that a deeper state of remission may be within reach for at least some people with lupus. DORIS+ aims to better define what that could mean.

This matters because remission is an important concept for research, clinical care and people living with lupus.

🦋 Lupus Europe is proud to be part of this important taskforce alongside many lupologists and researchers including Prof. Laurent Arnaud, Prof. Ronald van Vollenhoven, Prof. Zahi Touma, Prof. David Isenberg, Prof. Mariele Gatto, Prof. Ioannis Parodis, Prof. Eloisa Bonfá, Prof. Frédéric A. Houssiau, Prof. Andrea Doria, Prof. Ricard Cervera and Prof. Maarten Limper.

😃 We will keep you updated!
... See MoreSee Less

Image attachment
Image attachment
Image attachment
Image attachment
LUPUS EUROPE Uniting people with Lupus throughout Europe
Send